Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...

Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.

This economic evaluation found that although tirzepatide and semaglutide offered substantial long-term health benefits, they were not ...

A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at ...

The Outsourcing Facilities Association is appealing a ruling that rejected their request for an injunction against the FDA’s ...

Researchers analysed data from 150 adults with T1D, divided into semaglutide, tirzepatide, and control groups.

Obesity is a common health problem affecting a considerable (and growing) proportion of adult populations worldwide.1 Although overweight and obesity are usually diagnosed by anthropometry, such as ...

In one of the first real-world studies, Tirzepatide shows impressive weight loss results for people without diabetes—shedding nearly 13% of body weight in just six months. Study: Real-world use ...

Viking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its ...

A recent study published in Diabetes Technology & Therapeutics has demonstrated that the off-label use of semaglutide and ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.